In September 2016 belimumab (Benlysta), the first new treatment for lupus in more than 50 years, was finally approved by NICE for limited use on the NHS for certain patients living with SLE in England and Wales. This managed access agreement (MAA) applies until October 2020 or the publication of NICE’s review (whichever is sooner).
As of March 2019, only 113 patients had been prescribed belimumab in the NHS in England. This is fewer than expected and therefore NICE, the University of Manchester (acting on behalf of BILAG-BR), LUPUS UK, NHS England and GSK have signed a joint letter addressing some of the main issues that have been suggested as contributing to the lower than anticipated uptake.
The letter can be read by clicking the button below;